Compare MXL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | VTVT |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 127.0M |
| IPO Year | 2010 | 2015 |
| Metric | MXL | VTVT |
|---|---|---|
| Price | $17.41 | $34.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $20.25 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 1.4M | 12.4K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $423,372,000.00 | $17,000.00 |
| Revenue This Year | $30.54 | N/A |
| Revenue Next Year | $18.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.53 | N/A |
| 52 Week Low | $8.35 | $13.15 |
| 52 Week High | $25.73 | $35.95 |
| Indicator | MXL | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 70.06 |
| Support Level | $15.18 | $22.92 |
| Resistance Level | $19.64 | $35.95 |
| Average True Range (ATR) | 0.83 | 2.23 |
| MACD | 0.26 | 0.59 |
| Stochastic Oscillator | 60.37 | 89.87 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.